In vitro characterisation of the muscarinic receptor partial agonist, sabcomeline, in rat cortical and heart membranes

European Journal of Pharmacology

Volumn 370, Issue 1, 1999, Pages 69-77

  Watson, Jeannette M ^a   Hunter, A Jaqueline ^a   Brown, Anthony M ^a   Middlemiss, Derek N ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

35S GTP S binding; Adenylyl cyclase; Cortex, rat; Heart, rat; Phosphoinositide hydrolysis; Radioligand binding; Sabcomeline

Indexed keywords

ADENYLATE CYCLASE; ATROPINE; CARBACHOL; HIMBACINE; MILAMELINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR; OXOTREMORINE; PHOSPHATIDYLINOSITIDE; PIRENZEPINE; QUINUCLIDINYL BENZILATE; RECEPTOR SUBTYPE; SABCOMELINE; XANOMELINE;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; HEART MUSCLE FIBER MEMBRANE; NONHUMAN; PHOSPHOINOSITIDE METABOLISM; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY;

ADENYLATE CYCLASE; ANIMALS; CARBACHOL; CELL MEMBRANE; CELLS, CULTURED; CEREBRAL CORTEX; DRUG INTERACTIONS; HEART; IMINES; MALE; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; MUSCLE, SMOOTH, VASCULAR; MYOCARDIUM; OXOTREMORINE; QUINUCLIDINES; QUINUCLIDINYL BENZILATE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032899659     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00081-3     Document Type: Article

References (45)

1. Baumgold J., Drobnick A. An agonist that is selective for adenylate cyclase-coupled muscarinic receptors. Mol. Pharmacol. 36:1989;465-470.
2. Bonner T.I. The molecular basis of muscarinic receptors. Trends Neurosci. 12:1989;149-151.
3. Bonner T.I., Buckley N.J., Young A.C., Brann M.R. Identification of a family of muscarinic acetylcholine receptor genes. Science (Washington, DC). 237:1987;527-532.
4. 5 muscarinic acetylcholine receptor genes. Neuron. 1:1988;403-410.
5. Bowen, D.M., 1983. Biochemical assessment of neurotransmitter and metabolic dysfunction and cerebral atrophy in Alzheimer's Disease. In: Katzman, R. (Ed.), Banbury Report 15. Cold Spring Harbour, pp. 219-232.
6. Brann M.R., Conklin B., Dean N.M., Collins R.M., Bonner T.I., Buckley N.J. Cloned muscarinic receptors can couple to different G-proteins and second messengers. Soc. Neurosci. 14:1988;600. Abstr.
7. Brown F., Clark M., Graves D., Hadley M., Hatcher J., McArthur R., Riley G., Semple J. Variations of muscarinic activities of oxotremorine analogues. Drug Dev. Res. 14:1988;343-347.
8. Buckley, N.J., Caulfield, M., 1992. Transmission: acetylcholine. In: Burnstock., G., Hoyle, C. (Eds.), Autonomic Neuroeffector Mechanisms. Harwood, Reading, pp. 257-332.
9. Caulfield, M.P., Birdsall, N.J.M., 1998. International union of pharmacology: XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 279-290.
10. 1 receptors. Neurobiology of Aging. 17(4F):1996;S161.
11. 1A autoreceptor in vivo. Br. J. Pharmacol. 124:1998;206-212.
12. Coyle J.T., Price D.L., Delong M.R. Alzheimer's Disease: a disorder of cortical cholinergic innervation. Science. 219:1983;1185-1190.
13. Davies P., Maloney A.J.F. Selective loss of central cholinergic neurons in Alzheimer's Disease. Lancet. 2:1976;1403.
14. Davies P., Verth A. Regional distribution of muscarinic acetylcholine receptors in normal and Alzheimer's-type dementia brain. Brain Res. 138:1977;385-392.
15. 3 receptors. J. Pharmacol. Exp. Ther. 241(1):1987;257-262.
16. Dorje F., Wess J., Lambrecht G., Tacke R., Mutschler E., Brann M.R. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 256:1990;727-733.
17. Eglen R.M., Hegde S.S., Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol. Rev. 48:1996;531-565.
18. Ehlert F.J., Delen F.M., Yun S.H., Friedman D.J., Self D.W. Coupling of subtypes of the muscarinic receptor to adenylate cyclase in the corpus striatum and heart. J. Pharmacol. Exp. Ther. 251:1989;660-671.
19. Ehlert F.J., Ostrom R.S., Sawyer G.W. Subtypes of the muscarinic receptor in smooth muscle. Life Sci. 61:1997;1729-1740.
20. 3 muscarinic receptors in the rat peripheral lung. Biochem. Pharmacol. 52:1996;643-658.
21. 3 muscarinic receptor subtypes in primate brain Synapse. 14:1993;283-296.
22. Freedman S.B., Harley E.A., Iversen L.L. Relative affinities of drugs acting at cholinoreceptors in displacing agonist and antagonist radioligands: the NMS/OXO-M ratio as an index of efficacy at cortical muscarinic receptors. Br. J. Pharmacol. 93:1988;437-445.
23. 4 receptors mediating nonadrenergic noncholinergic relaxations in rabbit anococcygeus muscle. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;505-516.
24. + ions. Eur. J. Pharmacol. 172:1989;155-163.
25. Lazareno S., Birdsall N.J.M. Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusof equations. Br. J. Pharmacol. 109:1993;1110-1119.
26. 4 receptors: antagonist studies Br. J. Pharmacol. 109:1993;1120-1127.
27. 4 binding sites in rabbit lung, chicken heart, and NG108-15 cells. Mol. Pharmacol. 38:1990;805-815.
28. Lehericy S., Hirsch E.C., Cervera-Pierot P., Hersh L.B., Bakchine S., Piette F., Duyckaerts C., Hauw J.-J., Javoy-Agid F., Agid Y. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's Disease. J. Comp. Neurol. 330:1993;15-31.
29. 5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 52:1993;441-448.
30. Levey A.I., Kitt C.A., Simonds W.F., Price D.L., Brann M.R. Identification and localisation of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 11:1991;3218-3226.
31. Liao C.F., Themmen A.P., Joho R., Barberis C., Birnbaumer M., Birnbaumer L. Molecular cloning and expression of a fifth muscarinic acetylcholine receptor. J. Biol. Chem. 264:1989;7328-7337.
32. 1 partial agonist, enhances cognition at doses which do not induce side effects. Neurobiology of Aging. 17(4F):1996;S30.
33. 1 receptors. J. Pharmacol. Exp. Ther. 283:1997;1059-1068.
34. 2 muscarinic receptors in the cerebral cortex in Alzheimer's Disease and experimental cholinergic denervation. Science. 228:1985;1115-1117.
35. Novotny E.A., Brann M.R. Agonist pharmacology of cloned muscarinic receptors. Trends Pharmacol. Sci. 4:1989;116. Suppl.
36. Pedder E.K., Eveleigh P., Poyner D., Hulme E.C., Birdsall N.J. Modulation of the structure-binding relationship of antagonists for muscarinic acetylcholine receptor subtypes. Br. J. Pharmacol. 103:1991;1561-1567.
37. Peralta E.G., Ashkenazi A., Winslow J.W., Ramachandran J., Capon D.J. Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes. Nature (London). 334:1988;434-437.
38. 4 muscarinic receptors. J. Pharmacol. Exp. Ther. 284:1998;707-713.
39. Salomon Y. Adenylate cyclase assay. Adv. Cyclic Nucleotide Res. 10:1979;35-55.
40. Sedman A.J., Bockbrader H., Schwarz R.D. Preclinical and phase 1 clinical characterisation of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's Disease. Life Sci. 56:1995;877-882.
41. 1 receptors. J. Pharmacol. Exp. Ther. 269:1994;271-281.
42. 1A receptor agonists on 5-HT release in rat brain in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 348:1993;339-346.
43. 2 receptors. Br. J. Pharmacol. 125:1998;1413-1420.
44. 2 receptors coupled to inhibition of adenylate cyclase in rat heart. Chin. J. Physiol. 33:1990;315-327.
45. Wesnes K., Warburton D.M. Effects of scopolamine and nicotine in human rapid information processing performance. Psychopharmacology. 82:1984;147-150.